HTG Molecular Diagnostics Inc (NASDAQ:HTGM)’s share price traded up 1.1% during mid-day trading on Wednesday . The company traded as high as $2.70 and last traded at $2.65, with a volume of 61,040 shares. The stock had previously closed at $2.62.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday. Canaccord Genuity reissued a “buy” rating and issued a $10.00 price objective on shares of HTG Molecular Diagnostics in a report on Tuesday, March 22nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $5.00 price objective (down previously from $10.00) on shares of HTG Molecular Diagnostics in a report on Monday, March 28th.

The firm’s 50-day moving average is $2.78 and its 200 day moving average is $2.98. The stock’s market cap is $18.57 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by $0.19. On average, analysts forecast that HTG Molecular Diagnostics Inc will post ($3.91) EPS for the current fiscal year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.